产品名称	NCI-H1650人非小细胞肺癌细胞
货号	ZQ0385
产品介绍	人非小细胞肺癌细胞NCI-H1650 [H-1650, H1650]建系于1987年五月，从一名罹患支气管肺泡癌（3B阶段）的27岁白人男性的胸腔积液中分离获得。该患者吸烟。
种属	人
性别/年龄	男/27岁
组织	肺；来源于转移部位:胸腔积液
疾病	3B期，腺癌；支气管肺泡癌
细胞类型	肿瘤细胞
形态学	上皮细胞
生长方式	贴壁
倍增时间	大约40.4~42小时
培养基和添加剂	RPMI-1640（品牌：中乔新舟 货号：ZQ-200）+10%FBS（品牌：中乔新舟 货号:ZQ500-A）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0385
生物安全等级	BSL-1
STR位点信息	Amelogenin: X CSF1PO: 11 D13S317: 11 D16S539: 11,12 D5S818: 11 D7S820: 8,9 TH01: 9.3 TPOX: 11 vWA: 18
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达
基因表达
保藏机构	ATCC; CRL-5883
供应限制	仅供科研使用

货号	ZQ0385
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： Tartrate-Resistant Acid Phosphatase 5/ACP5 Interacts with p53 to Control the Expression of SMAD3 in Lung Adenocarcinoma
DOI： 10.1016/j.omto.2020.01.010
发表时间： 2020-02-08
期刊： Molecular Therapy-Oncolytics
影响因子： 7.2
货号： ZQ0385
产品名称： NCI-H1650 cells

原文链接： https://www.sciencedirect.com/science/article/pii/S2372770520300206

论文标题： miR‐363‐3p inhibits migration, invasion, and epithelial–mesenchymal transition by targeting NEDD9 and SOX4 in non‐small‐cell lung cancer
DOI： 10.1002/jcp.29099
发表时间： 2019-07-22
期刊： JOURNAL OF CELLULAR PHYSIOLOGY
影响因子： 4.522
货号： ZQ0385
产品名称： NCI-H1650 cells
原文链接： https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.29099

论文标题： MicroRNA‐198‐5p inhibits the migration and invasion of non‐small lung cancer cells by targeting fucosyltransferase 8
DOI： 10.1111/1440-1681.13154
发表时间： 2019-08-30
期刊： CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
影响因子： 2.336
货号： ZQ0385
产品名称： NCI-H1650 cells
原文链接： https://onlinelibrary.wiley.com/doi/abs/10.1111/1440-1681.13154

论文标题： Loading MicroRNA-376c in Extracellular Vesicles Inhibits Properties of Non-Small Cell Lung Cancer Cells by Targeting YTHDF1:
DOI： 10.1177/1533033820977525
发表时间： 2020-12-07
期刊： TECHNOLOGY IN CANCER RESEARCH & TREATMENT
影响因子： 2.074
货号： ZQ0385
产品名称： NCI-1650 cells

原文链接： https://journals.sagepub.com/doi/abs/10.1177/1533033820977525

PubMed=1311061
Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Oncogene 7:171-180(1992)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339
Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Cancer Res. 67:2046-2053(2007)

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025
Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Cell 131:1190-1203(2007)

PubMed=19472407; DOI=10.1002/humu.21028
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=22433462; DOI=10.1186/1471-2407-12-95
Ghosh G., Lian X.-J., Kron S.J., Palecek S.P.
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
BMC Cancer 12:95.1-95.14(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)